Bayer supporting GARFIELD, an atrial fibrillation registry

A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.